Royalty Pharma PLC $RPRX Shares Sold by C WorldWide Group Holding A S

C WorldWide Group Holding A S lowered its holdings in Royalty Pharma PLC (NASDAQ:RPRX) by 28.7% in the second quarter, HoldingsChannel reports. The firm owned 471,881 shares of the biopharmaceutical company’s stock after selling 189,895 shares during the period. Royalty Pharma comprises about 0.7% of C WorldWide Group Holding A S’s portfolio, making the stock its 26th largest holding. C WorldWide Group Holding A S’s holdings in Royalty Pharma were worth $26,458,000 as of its most recent SEC filing.

Other hedge funds have also recently bought and sold shares of the company. LM Advisors LLC acquired a new position in shares of Royalty Pharma in the 4th quarter valued at approximately $26,000. Lloyd Advisory Services LLC. acquired a new stake in shares of Royalty Pharma during the fourth quarter worth approximately $30,000. Blue Trust Inc. increased its stake in shares of Royalty Pharma by 173.4% in the first quarter. Blue Trust Inc. now owns 689 shares of the biopharmaceutical company’s stock worth $33,000 after buying an additional 437 shares during the last quarter. CIBC Private Wealth Group LLC raised its holdings in Royalty Pharma by 66.4% in the fourth quarter. CIBC Private Wealth Group LLC now owns 1,118 shares of the biopharmaceutical company’s stock valued at $43,000 after acquiring an additional 446 shares in the last quarter. Finally, Larson Financial Group LLC raised its holdings in Royalty Pharma by 31.9% in the third quarter. Larson Financial Group LLC now owns 1,264 shares of the biopharmaceutical company’s stock valued at $45,000 after acquiring an additional 306 shares in the last quarter. Institutional investors and hedge funds own 54.35% of the company’s stock.

Insiders Place Their Bets

In other Royalty Pharma news, EVP Marshall Urist sold 9,099 shares of the firm’s stock in a transaction on Wednesday, July 1st. The stock was sold at an average price of $55.88, for a total value of $508,452.12. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Christopher Hite sold 100,000 shares of the stock in a transaction dated Tuesday, August 18th. The stock was sold at an average price of $59.97, for a total transaction of $5,997,000.00. Following the completion of the sale, the executive vice president directly owned 370,401 shares in the company, valued at approximately $22,212,947.97. This trade represents a 21.26% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 398,197 shares of company stock worth $22,513,280 over the last quarter. 18.84% of the stock is currently owned by company insiders.

Royalty Pharma Stock Performance

Shares of NASDAQ RPRX opened at $60.59 on Wednesday. The company has a quick ratio of 2.80, a current ratio of 2.80 and a debt-to-equity ratio of 0.88. The firm’s 50-day moving average price is $59.20 and its two-hundred day moving average price is $53.38. Royalty Pharma PLC has a 52-week low of $34.63 and a 52-week high of $64.38. The stock has a market capitalization of $34.84 billion, a P/E ratio of 41.79, a P/E/G ratio of 1.49 and a beta of 0.44.

Royalty Pharma (NASDAQ:RPRX) last issued its earnings results on Wednesday, August 5th. The biopharmaceutical company reported $1.32 EPS for the quarter, beating analysts’ consensus estimates of $1.27 by $0.05. The company had revenue of $674.14 million during the quarter, compared to the consensus estimate of $758.93 million. Royalty Pharma had a return on equity of 30.01% and a net margin of 32.14%. As a group, sell-side analysts forecast that Royalty Pharma PLC will post 5.3 earnings per share for the current year.

Royalty Pharma Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Thursday, September 10th. Shareholders of record on Friday, August 14th will be given a $0.235 dividend. The ex-dividend date of this dividend is Friday, August 14th. This represents a $0.94 annualized dividend and a yield of 1.6%. Royalty Pharma’s dividend payout ratio (DPR) is currently 64.83%.

Analyst Ratings Changes

Several brokerages have weighed in on RPRX. Wall Street Zen lowered shares of Royalty Pharma from a “strong-buy” rating to a “buy” rating in a report on Sunday, August 30th. TD Cowen increased their price target on shares of Royalty Pharma from $65.00 to $68.00 and gave the stock a “buy” rating in a research report on Tuesday. JPMorgan Chase & Co. boosted their price objective on Royalty Pharma from $58.00 to $62.00 and gave the company an “overweight” rating in a report on Friday, August 7th. The Goldman Sachs Group restated a “buy” rating and set a $66.00 price objective on shares of Royalty Pharma in a research note on Thursday, August 6th. Finally, Morgan Stanley reaffirmed an “overweight” rating and set a $65.00 target price on shares of Royalty Pharma in a report on Thursday, August 6th. Eight analysts have rated the stock with a Buy rating, According to MarketBeat, Royalty Pharma has an average rating of “Buy” and an average price target of $61.29.

Royalty Pharma Company Profile

Royalty Pharma plc is a specialty finance company that acquires biopharmaceutical royalty interests and provides non-dilutive financing to drug developers and rights holders. The firm purchases future royalty streams, milestone-contingent payments and other revenue rights linked to approved and late-stage pharmaceutical and biotechnology products. By paying upfront consideration for these rights, Royalty Pharma seeks to generate long-term cash flows tied to the commercial performance of a diversified portfolio of medicines.

The company’s transaction structures include outright royalty purchases, structured financings and milestone arrangements tailored to the needs of innovator companies, academic institutions and investors.